Patent ID: 8071292

Claim:
A method of diagnosing whether a human subject has or is at risk for developing indolent chronic lymphocytic leukemia and distinguishing indolent chronic lymphocytic leukemia from aggressive chromosome 11-normal leukemia, comprising: measuring miR-29b and miR-181b gene product levels in a test sample from a human subject suspected of having or developing indolent chronic lymphocytic leukemia, and comparing the miR-29b and miR-181b gene product levels in the test sample to the miR-29b and miR-181b gene product levels of an aggressive chromosome 11-normal leukemia control sample, wherein increased miR-29b and miR-181b gene product levels in the test sample compared to the control sample indicate and distinguish that the human subject has or is at risk for developing indolent chronic lymphocytic leukemia.